Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Dana-Farber Cancer Institute and Quest Diagnostics collaborate to identify the prevalence of COVID-19 in individuals with precursor to multiple myeloma
2 New Infusion Center Unveiled at UAMS' Cancer Institute
3 Hitting a New Target in Multiple Myeloma
4 New trial for bone marrow cancer patients facing poor outcomes
5 FDA Lifts Clinical Hold on MELANI-01 Trial With CAR T Product UCARTCS1 in Myeloma
6 Ascentage Pharma Receives Approvals for Two Phase Ib/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenström Macroglobulinemia and Multiple Myeloma in China
7 Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
8 Latest News: A World Beyond Chemo
10 New cancer drug for difficult tumour types
11 Legend Biotech Announces ASH 2020 Data Presentations for Ciltacabtagene Autoleucel (cilta-cel), an Investigational BCMA CAR-T Cell Therapy in Development for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
12 Praise and Applause; Disappearing Prostate Cancer; Eliminating Cervical Cancer
13 Christine Little obituary
14 New drug for difficult-to-drug cancer mutation could be key treatment for a range of cancers
15 Evaluating The Potential Impact Of Anti-BCMA Therapies In The Multiple Myeloma Space
16 Karyopharm Announces Ongoing Phase 3 SIENDO Study of XPOVIO® (Selinexor) in Patients with Endometrial Cancer Passes Planned Interim Futility Analysis: Data and Safety Monitoring Board Recommends the Study Should Proceed as Planned Without Any Modifications
17 Out of the dark age
18 Usmani Highlights Impact of Latest Daratumumab Triplet Approval in Lenalidomide-Refractory Myeloma
19 James Benjamin | Obituary | The Eagle Tribune
20 Management of AL Amyloidosis, Immunoglobulin Deposition Disease During the COVID-19 Pandemic
21 Gene Therapies: What to Know | Patient Advice | US News
22 Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
23 Institute issues draft scoping plan for review of anti-BCMA therapies for multiple myeloma
24 Approval of Multiple Myeloma Drug Isatuximab Improves Patients' Prospects
25 Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma
26 KRAS Inhibitors Show Promise in Early Studies
27 Research institute to evaluate clinical effectiveness, value of CAR-T for multiple myeloma
28 Riney Foundation gives $7.8 million to Winship for multiple myeloma research
29 Can Acrylic Nails Cause Cancer?
30 The COVID challenge: Maintaining progress in multiple myeloma clinical investigation
31 Wugen Appoints New Vice President and Head of NK Research as the Company Continues to Expand its Pipeline
32 Winship receives $7.8 million for multiple myeloma research
33 Scottrade founder Rodger Riney gives Emory University's Winship Cancer Institute $7.8M
34 Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma
35 Medical license not renewed for head of UAMS Medical Center's Myeloma Institute
36 $1.9M Grant Awarded for Study on How Fat Cells Help Myeloma Cells...
37 UAMS researcher awarded $1.7 million to study bone health in myeloma patients
38 Study of SAC's Role in Multiple Myeloma and Erythropoietin-Induced Osteoporosis
39 New CAR-T target yields promising results for multiple myeloma
40 Immune system changes occur early in development of multiple myeloma, study finds
41 UAMS audit finds $29M deficit; center used restricted funds, system trustees told
42 New Drug Regimens Show Promise in Early and Late Myeloma
43 UAMS Myeloma Center Awarded National Grant from Leukemia & Lymphoma Society
44 Guide to Multiple Myeloma: Overview
45 Dana-Farber establishes new research center with $16.5M gift
46 Multiple Myeloma Treatment Paradigm Improved Markedly In Recent Years
47 ONCOTracker, Binding Site Team Up to Develop sBCMA Monitoring Test
48 Sarclisa Combo for Myeloma Approved for NHS Use in England, Wales
49 NCI Awards $1.7M for Bone Therapy Research to Prevent or Delay...
50 Red Hill Biopharma, which has an HQ in Raleigh, to expand production capability
51 Stand Up to Cancer Awards $100K for Research About Precursor...
52 VIDEO: BCMA-targeted CAR T offers 'attractive option' for advanced multiple myeloma
53 Patient and Author with Multiple Myeloma is Writing His Own Next Chapter
54 What Are the Health Care Access and Quality Factors in Multiple Myeloma Survival?
55 Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients
56 Changing Patterns of Care in Multiple Myeloma
57 Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
58 COVID-19: Rates of Hospitalization and Mortality Among Patients With Multiple Myeloma
59 Study Identifies Independent Predictors of Smoldering Multiple Myeloma Progression
60 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Met
61 State of the Science for Multiple Myeloma: Change in the Right Direction
62 Multiple Myeloma Scorecard: Efficacy, Cost, and Safety
63 MMRF CureCloud Study Launches to Democratize Access to Genomic Data in Multiple Myeloma
64 Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
65 FDA Issues Clinical Hold on CAR-T Cell Trial for Patients With Myeloma
66 Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting
67 CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells
68 UK's NICE Issues Draft 'No' Decision for Sarclisa Triple Combo
69 After Cancer Diagnosis, Hospital CEO Continues to Lead Through COVID-19
70 Myeloma specialists join NYU Langone Health's Center for Blood Cancers
71 Myeloma Treatment
72 Multiple Myeloma Fails to Keep Football Player-Turned-Broadcaster Out of Action
73 Highlighting Therapeutic Options in Later Lines for Multiple Myeloma
74 A Study Comparing Daratumumab and Lenalidomide as Maintenance Therapy for Multiple Myeloma
75 Cancer Patient Faces Multiple Diagnoses with the Strength of a Warrior
76 Dr. Richard on the Evolving Armamentarium in Multiple Myeloma
77 Multiple Myeloma Patients Best Treated at Recognized Care Centers...
78 CAR T-cell therapy could 'revolutionize' treatment of advanced multiple myeloma
79 Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
80 Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma
81 Cancer patients continue fights of their own while on guard against coronavirus
82 10 important updates in multiple myeloma
83 Patients with Multiple Myeloma and CHIP Face Worse Outcomes Following ASCT
84 Paper Outlines Treatment Recommendations for Multiple Myeloma in Era of COVID-19
85 Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma
86 Dr. Lonial on Emerging Concepts in Multiple Myeloma Treatment
87 Internationally Known Multiple Myeloma Expert Dr. Gareth Morgan Coming to Arkansas from London to Lead UAMS Myeloma Institute
88 Matous Evaluates Treatment Strategies for Transplant-Ineligible Multiple Myeloma
89 FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma
90 FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
91 Expanded Access to Belantamab Mafodotin for People with Multiple Myeloma
92 Novel Triplet Combos Offer Deep Remissions in Relapsed/Refractory Multiple Myeloma
93 Daratumumab Becomes Treatment Staple in Newly Diagnosed Multiple Myeloma
94 New Weapons in the Battle Against Blood Cancers: Current Articles
95 A Phase I Study of CC-98633 CAR T-Cell Therapy in People with Recurrent or Persistent Multiple Myeloma
96 IMF, Medscape Oncology Offer Medical Education Series on...
97 Novel CAR-T Cell Therapy Shows Promise in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
98 Severe Renal Impairment Worsens Outcomes in Multiple Myeloma
99 Institute Researchers Take Lead in Trials of Potential COVID-19 Therapies
100 UAMS Myeloma Center receives $542,486 grant from Leukemia & Lymphoma Society